LEADER 02496nam 2200697z- 450 001 9910557665403321 005 20220111 035 $a(CKB)5400000000044852 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76275 035 $a(oapen)doab76275 035 $a(EXLCZ)995400000000044852 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aThe Immunology and Biology of Brain Tumors 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (88 p.) 311 08$a3-0365-0102-9 311 08$a3-0365-0103-7 330 $aImmunotherapy has become a viable treatment modality for a variety of cancers (and referred to as Science Magazine's "Breakthrough of the Year" in 2013, as well as ASCO's "Advance of the Year" in both 2016 and 2017). This Special Issue is focused on the relevance of immunobiology in brain tumors, touching on elements of immune suppression, immune stimulation, and the immune microenvironment, with culminations in translational immunotherapy. 606 $aMedicine and Nursing$2bicssc 610 $aAddison's disease 610 $aadrenal insufficiency 610 $abevacizumab 610 $acerebral radiation necrosis 610 $acheckpoint inhibitors 610 $acraniopharyngioma 610 $adiffusion tensor imaging 610 $aexosomes 610 $aGBM-associated macrophages (GAMs) 610 $ageneralized q-ball imaging 610 $aglioblastoma multiforme (GBM) 610 $aglioma 610 $ahigh-grade glioma 610 $ainflammation 610 $aInterleukin-6 610 $amultiple resections 610 $aoncoantigen 610 $aoncomiR-21 610 $aPD-1 610 $aPD-L1 610 $apituitary neuroendocrine tumors 610 $aSTAT3 inhibitor 610 $aTAM 610 $atreatment-related effects 610 $aTreg 610 $atumor angiogenesis 610 $atumor associate antigen 610 $atumor microenvironment (TME) 610 $avaccine therapy 610 $aVEGF 615 7$aMedicine and Nursing 700 $aGraner$b Michael$4edt$01327016 702 $aGraner$b Michael$4oth 906 $aBOOK 912 $a9910557665403321 996 $aThe Immunology and Biology of Brain Tumors$93037797 997 $aUNINA